Vivos Therapeutics Competitors and Similar CompaniesClear all

Vivos Therapeutics's competitors and similar companies include Acelity, Apria Healthcare Group, Shanghai Sanyou Medical and Endologix.

	Vivos Therapeutics Vivos Therapeutics is a company that specializes in the treatment of sleep and breathing disorders.	Acelity Acelity is a medical device company offering wound therapeutics products.	Apria Healthcare Group Apria Healthcare Group is a company that provides home respiratory services and medical equipment.	Shanghai Sanyou Medical Shanghai Sanyou Medical (上海三友医疗器械股份有限公司) researches, develops, manufactures, and supplies orthopedics implant products.	Endologix Endologix is a medical device company that provides therapies for the treatment of vascular disease.
Founding Date	Founding Date 2013	Founding Date 1976	Founding Date N/A	Founding Date 2005	Founding Date 1992
Type	Type Public	Type Subsidiary	Type Subsidiary	Type Public	Type Subsidiary
Tags	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy	Tags Healthcare medical devices therapy
Locations	Locations Highlands Ranch, US HQ	Locations San Antonio, US HQ Lane Cove West, AU Wien, AT Wien, AT Mississauga, CA see more	Locations Indianapolis, US HQ Lake Forest, US	Locations CN HQ	Locations Irvine, US HQ 's Hertogenbosch, NL Milpitas, US Santa Rosa, US
Employees	Employees 1094% decrease	Employees 2,106	Employees 5,666	Employees 466	Employees 4351% increase
Valuation ($)	Valuation ($) 13.8 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 752.5 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $17.4m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) $1.1b (FY, 2021)	Revenue (est.) ¥446m (FY, 2024)	Revenue (est.) $143.4m (FY, 2019)
Cost of goods	Cost of goods $6.9m (FY, 2025)	Cost of goods N/A	Cost of goods $341.3m (FY, 2021)	Cost of goods ¥130m (FY, 2024)	Cost of goods $52.3m (FY, 2019)
Gross profit	Gross profit $10.5m (FY, 2025)	Gross profit N/A	Gross profit $804m (FY, 2021)	Gross profit ¥317.9m (FY, 2024)	Gross profit $91.1m (FY, 2019)
Net income	Net income ($21.2m) (FY, 2025)	Net income N/A	Net income $64.9m (FY, 2021)	Net income ¥12.1m (FY, 2024)	Net income ($64.8m) (FY, 2019)
Operating ⚠
Patients	Patients 15 k (Q3, 2020)	Patients N/A	Patients 2 m (FY, 2019)	Patients N/A	Patients N/A